Aquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone604-629-9223
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$25 million
Profitability
Miscellaneous
Employees8
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Aquinox Pharmaceuticals (NASDAQ:AQXP) Frequently Asked Questions
What is Aquinox Pharmaceuticals' stock symbol?
Aquinox Pharmaceuticals trades on the NASDAQ under the ticker symbol "AQXP."
How were Aquinox Pharmaceuticals' earnings last quarter?
Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) issued its quarterly earnings data on Thursday, November, 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.43. View Aquinox Pharmaceuticals' Earnings History.
When is Aquinox Pharmaceuticals' next earnings date?
What price target have analysts set for AQXP?
4 brokerages have issued 12-month price objectives for Aquinox Pharmaceuticals' shares. Their forecasts range from $25.00 to $26.00. On average, they expect Aquinox Pharmaceuticals' stock price to reach $25.50 in the next twelve months. This suggests a possible upside of 837.5% from the stock's current price. View Analyst Price Targets for Aquinox Pharmaceuticals.
What is the consensus analysts' recommendation for Aquinox Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aquinox Pharmaceuticals in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aquinox Pharmaceuticals.
What are Wall Street analysts saying about Aquinox Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aquinox Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. " (7/2/2018)
- 2. Cantor Fitzgerald analysts commented, ": We are downgrading our opinion of AQXP stock from and we are lowering our PT from $28 to $2. LEADERSHIP-301 trial and the decision to discontinue all rosiptor development leaves the company with little value other than cash, in our opinion." (6/27/2018)
- 3. Needham & Company LLC analysts commented, "Aquinox reported 1Q18 financial results today and we spoke with mgmt for an update. The rosiptor Phase 3 LEADERSHIP trial in Interstitial Cystitis (IC)/ Bladder Pain Syndrome (BPS) remains on track for top-line results in 3Q18, most likely in July. 12wk trial was completed in Feb 2018. We expect a positive outcome based on Phase 2 data. Mgmt plans to revisit Phase 3 design w/ FDA prior to initiation of a planned second Phase 3 trial, which we believe may begin around YE18. Patient screening in a Phase 2 trial of rosiptor in Chronic Prostatitis (CP/ CPPS) is underway. Reiterate BUY. We do not believe the stock adequately reflects value of rosiptor program in BPS/IC." (5/8/2018)
Has Aquinox Pharmaceuticals been receiving favorable news coverage?
News stories about AQXP stock have trended somewhat positive this week, according to InfoTrie. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Aquinox Pharmaceuticals earned a daily sentiment score of 1.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near term.
Who are some of Aquinox Pharmaceuticals' key competitors?
Some companies that are related to Aquinox Pharmaceuticals include Kala Pharmaceuticals (KALA), Verrica Pharmaceuticals (VRCA), Strongbridge Biopharma (SBBP), Urovant Sciences (UROV), Calithera Biosciences (CALA), Kamada (KMDA), Athersys (ATHX), Xenon Pharmaceuticals (XENE), Dova Pharmaceuticals (DOVA), Marinus Pharmaceuticals (MRNS), Cerecor (CERC), Molecular Templates (MTEM), TapImmune (MRKR), Protagonist Therapeutics (PTGX) and Syros Pharmaceuticals (SYRS).
What other stocks do shareholders of Aquinox Pharmaceuticals own?
Who are Aquinox Pharmaceuticals' key executives?
Aquinox Pharmaceuticals' management team includes the folowing people:
- Mr. David J. Main, Co-Founder, Chairman, CEO & Pres (Age 54)
- Mr. Kamran Alam, CFO, VP of Fin. & Corp. Sec. (Age 45)
- Ms. Shelley McCloskey, VP of HR & Admin. (Age 59)
How do I buy shares of Aquinox Pharmaceuticals?
Shares of AQXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aquinox Pharmaceuticals' stock price today?
One share of AQXP stock can currently be purchased for approximately $2.72.
How big of a company is Aquinox Pharmaceuticals?
Aquinox Pharmaceuticals has a market capitalization of $64.02 million and generates $25 million in revenue each year. Aquinox Pharmaceuticals employs 8 workers across the globe.
What is Aquinox Pharmaceuticals' official website?
How can I contact Aquinox Pharmaceuticals?
Aquinox Pharmaceuticals' mailing address is 450-887 GREAT NORTHERN WAY, VANCOUVER A1, V5T 4T5. The company can be reached via phone at 604-629-9223 or via email at [email protected]
MarketBeat Community Rating for Aquinox Pharmaceuticals (NASDAQ AQXP)
MarketBeat's community ratings are surveys of what our community members think about Aquinox Pharmaceuticals and other stocks. Vote "Outperform" if you believe AQXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AQXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
